@ARTICLE{10.3389/bjbs.2023.11103, AUTHOR={Liau, Xiew Leng and Salvamani, Shamala and Gunasekaran, Baskaran and Chellappan, Dinesh Kumar and Rhodes, Anthony and Ulaganathan, Vaidehi and Tiong, Yee Lian}, TITLE={CCAT 1- A Pivotal Oncogenic Long Non-Coding RNA in Colorectal Cancer}, JOURNAL={British Journal of Biomedical Science}, VOLUME={80}, YEAR={2023}, URL={https://www.frontierspartnerships.org/articles/10.3389/bjbs.2023.11103}, DOI={10.3389/bjbs.2023.11103}, ISSN={2474-0896}, ABSTRACT={Colorectal cancer (CRC) is ranked as the third most common cancer and second deadliest cancer in both men and women in the world. Currently, the cure rate and 5-year survival rate of CRC patients remain relatively low. Therefore, discovering a novel molecular biomarker that can be used to improve CRC screening, diagnosis, prognosis, and treatment would be beneficial. Long non-coding RNA colon cancer-associated transcript 1 (CCAT 1) has been found overexpressed in CRC and is associated with CRC tumorigenesis and treatment outcome. CCAT 1 has a high degree of specificity and sensitivity, it is readily detected in CRC tissues and is significantly overexpressed in both premalignant and malignant CRC tissues. Besides, CCAT 1 is associated with clinical manifestation and advanced features of CRC, such as lymph node metastasis, high tumor node metastasis stage, differentiation, invasion, and distant metastasis. In addition, they can upregulate oncogenic c-MYC and negatively modulate microRNAs via different mechanisms of action. Furthermore, dysregulated CCAT 1 also enhances the chemoresistance in CRC cells while downregulation of them reverses the malignant phenotypes of cancer cells. In brief, CCAT 1 serves as a potential screening, diagnostic and prognostic biomarker in CRC, it also serves as a potential therapeutic marker to treat CRC patients.} }